



Cardiac Insight, Inc., Wearable Medical Device Company, Selected to Participate at Upcoming Cavendish Health Impact Forum on October 25, 2017

Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropic opportunities within health and the life sciences

Kirkland, WA (October 23, 2017) — Cardiac Insight, Inc., a U.S. developer of wearable medical devices and diagnostic software, announced today that the company has been selected to present at the upcoming Cavendish Health Impact Forum taking place October 25, 2017 in New York, NY, co-hosted by the Cavendish Impact Foundation and The John A. Hartford Foundation.

The Forum provides an environment for family offices, foundations and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. The Forum showcases presentations and panel discussions by leading family offices, foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Forums are hosted by leading institutions around the world.

Peter McCrea, President of the Cavendish Impact Foundation explains, “With the help of our expert team and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of **Cardiac Insight’s** research and scientific insights into advanced body-worn digital health devices and software analysis systems position them to make major contributions to the diagnosis and treatment of cardiac disease.”

“We are honored to be selected to present at the New York Forum. It is further recognition of our life- and cost-saving wearable ECG sensor, Cardea SOLO, and distinctive approach to improve cardiac arrhythmia and atrial fibrillation (AFib) detection, monitoring and treatment,” said Brad Harlow, Co-Founder and Chief Executive Officer of Cardiac Insight. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

The American Heart Association journal, *Circulation*, reported that 33.5 million people around the globe have AFib. According to the National Stroke Association, AFib raises a person's risk for stroke by 500 percent and most AFib-related strokes can be prevented. Millions more are dealing with hard-to-diagnose arrhythmias.

Cavendish consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over \$225 billion who share a passion for pro-social endeavors within health and the life sciences. Cavendish Forums provide impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by those actively seeking to accelerate technological innovation and health access. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about, with other impact investors from around the world.



About Cardiac Insight, Inc.
(www.cardiacinsightinc.com)

Cardiac Insight, Inc. is a U.S. developer of advanced body-worn digital health care information devices for cardiac, respiratory and other complex disease states. The company's technologies and systems are created using advanced algorithms and software that provide improvements in mean time to diagnosis. Cardiac Insight's mission is to invent complete and progressive solutions for unmet clinical needs on behalf of physicians, clients and payers. The company's flagship product, Cardea SOLO, is a wearable ECG sensor and software analysis system that is proving to enhance arrhythmia data reporting and time to diagnosis and treatment. Cardiac Insight was founded in 2008 and is based in Kirkland, WA.

For more information, contact info@cardiacinsightinc.com

About the Cavendish Impact Foundation
(<http://cavendishfoundation.org>)

The Cavendish Impact Foundation and Cavendish Global are a community of select innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy, and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work—through connectivity, advisory services, access to key experts, and capital opportunities. The upcoming Health Impact Forum will take place October 25, 2017 at the New York Athletic Club and is by invitation only. In 2018, Cavendish will host Forums in San Diego, South Florida, Washington, DC, Chicago, San Francisco, Cleveland, and the Northeast Corridor.

For more information, visit <http://cavendishglobal.com>

For Further Information, Contact:
Ian Kenyon
Vice President, Cavendish Global
Ian.Kenyon@CavendishGlobal.com